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The in vitro susceptibility of human- and bovine-origin Mycobacterium paratuberculosis to the thioupurine
drugs 6-mercaptopurine (6-MP) and azathioprine (AZA) was established using conventional plate counting
methods and the MGIT 960 ParaTB culture system. Both 6-MP and AZA had antibacterial activity against M.
paratuberculosis; isolates from Crohn’s disease patients tended to be more susceptible than were bovine-origin
isolates. Isolates of Mycobacterium avium, used as controls, were generally resistant to both AZA and 6-MP,
even at high concentrations (>64.0 g/ml). Among rapidly growing mycobacteria, Mycobacterium phlei was
susceptible to 6-MP and AZA whereas Mycobacterium smegmatis strains were not. AZA and 6-MP limited the
growth of, but did not kill, M. paratuberculosis in a dose-dependent manner. Anti-inflammatory drugs in the
sulfonamide family (sulfapyridine, sulfasalazine, and 5-aminosalycilic acid [mesalamine]) had little or no
antibacterial activity against M. paratuberculosis. The conventional antibiotics azithromycin and ciprofloxacin,
used as control drugs, were bactericidal for M. paratuberculosis, exerting their killing effects on the organism
relatively quickly. Simultaneous exposure of M. paratuberculosis to 6-MP and ciprofloxacin resulted in signif-
icantly higher CFU than use of ciprofloxacin alone. These data may partially explain the paradoxical response
of Crohn’s disease patients infected with M. paratuberculosis to treatment with immunosuppressive thiopurine
drugs, i.e., they do not worsen with anti-inflammatory treatment as would be expected with a microbiological
etiologic pathogen. These findings also should influence the design of therapeutic trials to evaluate antibiotic
treatments of Crohn’s disease: AZA drugs may confound interpretation of data on therapeutic responses for
both antibiotic-treated and control groups.
The etiology of Crohn’s disease remains elusive, but current
consensus opinion is that Crohn’s disease results from the inter-
play of host genetics and one or more environmental triggers (7).
Genetic markers for susceptibility to Crohn’s disease have been
discovered, notably the CARD15 (15, 21, 28) gene and most
recently the interleukin-23r (10) and ATG16L1 (16, 32) genes.
The increased incidence seen in many industrialized countries
supports the existence of an environmental trigger for Crohn’s
disease (11, 23, 37, 39, 43). Bacterial pathogens fit a pathobiology
model involving abnormal host response to infection resulting
from genetic defects in gastrointestinal antigen processing.
One trigger for Crohn’s disease may be Mycobacterium para-
tuberculosis, also referred to as Mycobacterium avium subsp.
paratuberculosis, with or without host genetic influences that
increase infection susceptibility or alter response to infection
(9, 40). M. paratuberculosis causes a type of chronic inflamma-
tory bowel disease in a wide array of ruminant species, as well
as in nonhuman primates (5, 18). The infection is prevalent in
domestic agriculture ruminants, and it has been diagnosed in
wildlife species as well. Human and animal M. paratuberculosis
isolates share common genotypes (12, 29). Exposure of hu-
mans to M. paratuberculosis could occur by both direct and
indirect contamination of food and water (3, 4, 44).
The thiopurine drugs azathioprine (AZA; Imuran) and its
metabolite 6-mercaptopurine (6-MP) are among the most
commonly used immunosuppressive drugs used to treat
Crohn’s disease symptoms (42). They both induce and maintain
Crohn’s disease remission. Compounds related to 5-amino-
salicyclates (sulfasalazine [SS] and mesalamine) are other
drugs used to suppress inflammation in Crohn’s disease pa-
tients (17). One observation arguing against an involvement of
M. paratuberculosis, or any other infectious agent, as a primary
cause of Crohn’s disease is that patients treated with immuno-
suppressive drugs do not clinically worsen (35).
Greenstein et al. demonstrated, however, that thiopurine
drugs inhibit the growth of M. paratuberculosis (13). The goal
of this study was to characterize 6-MP’s effect on M. paratu-
berculosis growth in culture and contrast it with the antibacte-
rial effects of conventional antimycobacterial antibiotics.
MATERIALS AND METHODS
Bacterial strains and inoculum preparation. A total of 11 bovine- and human-
origin M. paratuberculosis strains were used in this study (Table 1). All strains
were initially cultured in 7H9 broth supplemented with 10% (vol/vol) oleic
acid-albumin-dextrose-catalase (OADC; Becton Dickinson, Sparks, MD) and 2
g/ml of mycobactin J (Allied Monitor, Fayette, MO) for 1 month at 37°C. Seven
Mycobacterium avium strains were used for comparison. These were cultured in
7H9 broth supplemented with 10% OADC (Becton Dickinson, Sparks, MD) for
2 weeks to 1 month at 37°C (Table 1).
Three representatives of rapidly growing mycobacteria were tested: Mycobac-
terium phlei ATCC 11758, Mycobacterium smegmatis ATCC 14468, and M. smeg-
matis mc2155. Two nonmycobacterial strains, Escherichia coli ATCC 25922 and
Enterococcus faecalis ATCC 29212, were included as commonly used drug sus-
ceptibility control organisms (Table 1).
The identity of all mycobacteria was verified by multiplex PCR for insertion
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elements IS900, IS901, IS1311, and IS1245 (Johne’s Testing Center, Madison,
WI) as well as by high-pressure liquid chromatography (HPLC) of cell wall
mycolic acids by a reference laboratory (Wisconsin State Laboratory of Hygiene,
Madison, WI).
Single-cell suspensions of each strain were prepared as previously described
with slight modifications (41). Tenfold serial dilutions from seed lots of each
strain were plated on 7H10 agar, and single colonies were inoculated into MGIT
ParaTB tubes (Becton Dickinson, Sparks, MD) to quantify the number of or-
ganisms per ml (38). Seed lots of each strain were then kept in small aliquots at
80°C until use. After plate counting, 104 to 106 CFU of each strain were
inoculated to tubes of MGIT ParaTB medium to determine the average time to
detection (TTD) in the absence of drugs. For M. paratuberculosis in MGIT
ParaTB medium, the TTD is directly related to the number of organisms inoc-
ulated into each tube (38).
Drugs tested. All test drugs were obtained from Sigma-Aldrich Co., St. Louis,
MO, in a chemically pure form (purity  99.0%). The drugs were SS, 5-amino-
salicylic acid (5-ASA), sulfapyridine (SP), rifampin (RIF), nalidixic acid (NAL),
6-MP, AZA, azithromycin (AZM), and ciprofloxacin (CIP). Lyophilized drugs
were dissolved in appropriate diluents according to the manufacturer’s instruc-
tions. The drugs SS, 5-ASA, SP, 6-MP, and AZA were dissolved in 0.05 M NaOH
in 10 mM phosphate-buffered saline (PBS), RIF and NAL were dissolved in 10
mM PBS (pH 7.2), AZM was dissolved in 50% ethanol, and CIP was dissolved
in 0.5 N HCl in 10 mM PBS. All stock drug solutions were freshly prepared for
each experiment and filter sterilized using a 0.22-m polycarbonate syringe filter
(Millipore Corp., Bedford, MA).
MGIT 960 drug susceptibility testing. Methods published for M. tuberculosis
and M. avium susceptibility testing (1, 2, 20, 22, 31, 34) were adapted as closely
as possible; however, the significantly longer generation time of M. paratubercu-
losis compared to M. tuberculosis made this challenging. For this reason, we
performed drug susceptibility studies in three phases. First, we evaluated our
MGIT 960 antibacterial susceptibility testing method for M. paratuberculosis
ATCC 19698 by comparing MGIT 960 results with those of conventional agar
plate methods using drugs well characterized for antimycobacterial activity
(phase I). Second, we evaluated the effects of thiopurine drugs and 5-amino-
salicylates on M. paratuberculosis and M. avium growth in MGIT ParaTB me-
dium in comparison to conventional bactericidal antibiotics (phase II). Next, we
tested the reproducibility of the findings and expanded the study to include more
strains and mycobacterial species (phase III). Lastly, we tested the effect of a
combination of CIP and 6-MP over a range of achievable concentrations in tissue
on the viability of M. paratuberculosis (phase IV). The methods for each of the
four phases of study were as follows.
(i) Phase I. A single type strain of M. paratuberculosis, ATCC 19698, was tested
at three MGIT ParaTB medium inoculum levels (104, 105, and 106 CFU per
MGIT ParaTB tube). The final concentrations of each drug tested ranged from
1.0 to 64.0 g/ml.
(ii) Phase II. Phase II, designed based on the results of phase I, used seven
clinical strains of M. paratuberculosis of bovine or human origin and one M.
avium strain, ATCC 35712, as a control. Some drugs to which M. paratuberculosis
was not susceptible in phase I, specifically the SS drug family (SS, 5-ASA, and
SP), were excluded, and AZA, a prodrug of 6-MP, was added to the trial (19, 27).
(iii) Phase III. The reproducibility of findings in phase II was determined.
Additional strains of M. paratuberculosis also were tested, along with three other
species of mycobacteria. The thiopurine drug concentrations tested were the
same as in phase II, but one higher concentration (128.0 g/ml) was added for
some strains (see Table 4).
(iv) Phase IV. The effect of combined CIP and 6-MP on M. paratuberculosis
strain UCF-7 viability was determined over a range of concentrations (0, 2, 4, and
6 g/ml) and drug exposure times (0, 3, 6, 9, and 12 days). The results for this
drug combination for M. paratuberculosis counts were compared to those for
each drug individually, the drug-free control, and the 1% (1:100 original inocu-
lum dilution) drug-free control.
MGIT 960 methodology details. Serial dilutions of single-cell suspensions of
each mycobacterial strain were prepared, and 100 l was inoculated into MGIT
ParaTB medium (Becton Dickinson, Sparks, MD). Each tube contained 7 ml of
medium and a fluorescent indicator embedded in silicone on the bottom of the
tube. To each tube was added 800 l of MGIT ParaTB supplement (Becton
Dickinson, Sparks, MD), 500 l of egg yolk suspension (Becton Dickinson,
Sparks, MD), and 100 l of test drug, resulting in final concentrations of 0.5 to
64.0 g/ml. Tubes were incubated at 37°C in a MGIT 960 instrument and
removed when the instrument signaled them as being positive. Samples from all
signal-positive tubes were subcultured on Trypticase soy agar plates with 5%
sheep blood (Becton Dickinson, Sparks, MD) to check for contamination. Acid-
fast staining (Ziehl-Neelsen) was also performed on smears made from each
signal-positive tube to confirm the presence of mycobacteria. For E. coli and E.
faecalis, the standard broth microdilution method was used for susceptibility
tests (8).
Interpretation of susceptibility results. There are no interpretive criteria of
MGIT 960 algorithms for antibacterial susceptibility test interpretation for my-
cobacteria other than M. tuberculosis and M. avium. We used a similar interpre-
tation system with slight modifications (1, 2, 22, 33, 45). Briefly, positive control
MGIT ParaTB tubes were inoculated with only the test organism and the rele-
vant drug solvent (solvent control). For comparison, these drug-free solvent
control vials were inoculated with a 1:100 dilution of the normal organism
inoculum (designed to represent growth of 1% of the original bacterial popula-
tion). All MGIT ParaTB medium tubes were inoculated in duplicate with spec-
ified numbers of test organisms. In phase I trials, three M. paratuberculosis
TABLE 1. Bacterial strains tested in this study
Bacterial strain Isolate source
M. paratuberculosis
ATCC 19698 .......................................Bovine, clinical case of
paratuberculosis, type strain
JTC303.................................................Bovine, clinical case of
paratuberculosis, JTCa
UCF-3..................................................Human, Crohn’s disease
patient ileum, UCFb
UCF-4..................................................Human, Crohn’s disease
patient ileum, UCFb
UCF-5..................................................Human, Crohn’s disease
patient ileum, UCFb
UCF-7..................................................Human, Crohn’s disease
patient ileum, UCFb
UCF-8..................................................Human, Crohn’s disease
patient ileum, UCFb
B213 .....................................................Bovine, clinical case of
paratuberculosis, UCFb
B236 .....................................................Bovine, clinical case of
paratuberculosis, UCFb
B238 .....................................................Bovine, clinical case of
paratuberculosis, UCFb
B244 .....................................................Bovine, clinical case of
paratuberculosis, UCFb
M. avium
ATCC 35712 .......................................Chicken, TMC701,c serotype 2
ATCC 25291 .......................................Chicken, liver, TMC724,
serotype 2, type strain
104........................................................Human, AIDS patient,
serotype 1d
JTC48627.............................................Bison, fecal sample
JTC981.................................................Bongo, fecal sample
EPA3....................................................Water, WSLHe
WSLH1544..........................................Water, WSLH
Rapidly growing mycobacteria
M. phlei ATCC11758 .........................TMC1458, type strain
M. smegmatis ATCC14468 ................TMC1546, suggested neotype
M. smegmatis mc2155f ........................Transformably competent
isolate of mc26
Other bacterial speciesg
E. coli ATCC 25922...........................Clinical isolate, FDA strain
E. faecalis ATCC 29212 ....................Human urine
a JTC, Johne’s Testing Center, Madison, WI.
b Saleh Naser, University of Central Florida (UCF), Orlando, FL.
c Trudeau Mycobacterial Culture Collection.
d Obtained from A. M. Talaat (University of Wisconsin-Madison; originally
from Raul Barletta at the University of Nebraska).
e WSHL, Wisconsin State Hygiene Laboratory.
f Obtained from the American Type Culture Collection.
g Quality control strains used in antibiotic susceptibility testing.
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inoculum levels were tested (104, 105, and 106 CFU), and in phases II, III, and
IV only 105 to 106 CFU were inoculated to each MGIT ParaTB tube.
The bacterial growth rate in each MGIT ParaTB tube was defined by TTD,
i.e., the number of days the MGIT ParaTB tubes were incubated until they were
determined to be signal positive by the MGIT 960 instrument (38). The baseline
for M. paratuberculosis inhibition was defined as the day that the 1:100 dilution
inoculum control became signal positive. Thus the lowest concentration for each
test drug that inhibited growth was the concentration that produced a TTD
greater than that of the 1:100 dilution control tube. The minimum concentrations
of each drug that completely suppressed growth of the test organism in the
MGIT 960 system, i.e., the tubes were never signal positive by the end of the
experiment at 56 days postinoculation, were also reported. For MGIT ParaTB
tubes inoculated with 106 CFU M. paratuberculosis, this usually occurred between
days 5 and 7 of incubation.
If the positive control tube became signal positive earlier than incubation day
4, the M. paratuberculosis inoculum was considered too high. Similarly, if the
1:100 dilution inoculum control tube did not become signal positive within 8 days
after the positive control, the tube was considered underinoculated. If either
control tube criterion was not met, the test was considered invalid and the test
was repeated. An uninoculated MGIT ParaTB tube was used as the negative
control for every trial.
Agar plate counting method. Agar plate counting methods for drug suscepti-
bility testing were performed with 7H10 medium supplemented with 10% OADC
(Becton Dickinson, Sparks, MD) and 2 g/ml of mycobactin J (Allied Monitor,
Fayette, MO) for phase I, phase III, and phase IV trials (26). At selected times
after exposure to drugs, surviving M. paratuberculosis cells were quantified by
conventional plate counting for all controls and every drug concentration for the
106-CFU M. paratuberculosis inoculum in phase I. In phase III, plate counts were
done for only two concentrations of each drug, 2.0 g/ml (low concentration) and
16.0 g/ml (high concentration).
Bacteria were mixed with each specific drug and drug concentration in MGIT
ParaTB medium and incubated at 37°C. At 3 and 5 days postinoculation an
aliquot (0.1 ml) was removed for plate count determinations (note that MGIT
960 instrument readings were not taken on these tubes; the tubes merely pro-
vided the medium in which the bacterium-drug interaction took place). Bacterial
cells were harvested from MGIT tubes by centrifugation, resuspended in PBS,
and homogenized to break up bacterial cell clumps by vortexing with glass beads
(30). Then, 10-fold serial dilutions (100 to 106) were made in PBS, and 100 l
of each dilution was plated in quadruplicate on 7H10 agar supplemented 10%
OADC (Becton Dickinson, Sparks, MD) and 2 g/ml of mycobactin J (Allied
Monitor, Fayette, MO). The numbers of CFU were determined by visual inspec-
tion after incubation of plates at 37°C for 8 weeks. The lowest concentration of
each drug tested by the agar counting method that inhibited growth was defined
as the lowest concentration of the drug that produced a 99% (2 log10) reduction
in CFU. These concentrations were compared to those determined by MGIT 960
drug susceptibility testing.
Quality control. M. paratuberculosis strain ATCC 19698 was included in all
experiments and used to test the ability of each new lot of MGIT ParaTB
medium, growth supplement, egg yolk, and mycobatin J to support M. paratu-
berculosis growth. Also, E. coli ATCC 25922 and E. faecalis ATCC 29212 were
used as controls to assure drug efficacy, as these agents have predictable antibi-
otic susceptibility patterns. Solvent controls were used with each drug to distin-
guish anti-M. paratuberculosis activity due to solvents themselves from the activity
of the drugs, and uninoculated MGIT ParaTB medium controls served to detect
any contamination by extraneous organisms.
RESULTS
Phase I. Inoculum size is a critical factor in drug suscepti-
bility testing of slowly growing mycobacteria (31). Three M.
paratuberculosis ATCC 19698 inocula initially tested were 104,
105, and 106 CFU/tube. The average TTDs for inoculum con-
trols (drug solvent only) were 4.97, 7.89, and 10.76 days for 106,
105, and 104 CFU/tube, respectively. The 1:100 dilution inoc-
ulum controls became signal positive at 10.76, 14.32, 21.74 days
on average, respectively. The drug solvents had no effect on
TTD if 102 CFU M. paratuberculosis were inoculated (mul-
tiple comparison test, P 0.83; data not shown). However, the
104-CFU inoculum was excluded from subsequent analyses
because of the long incubation time required for the 1:100
dilution control to become signal positive, especially in the face
of drug solvents, notably 50% ethanol.
When the M. paratuberculosis inoculum was105 CFU/tube,
there was good agreement between MGIT 960- and agar plate-
determined drug effects, with previously reported mycobacte-
rium MIC ranges for all drugs tested (Table 2). An M. para-
tuberculosis inoculum amount of 105 versus 106 CFU did not
affect the drug effects for any compound with the exception of
RIF (data not shown). While the concentration of RIF needed
to inhibit M. paratuberculosis was low, the organism was able to
grow to some extent even in the face of the highest RIF
concentration tested, 64.0 g/ml.
Growth inhibition was seen at the lowest concentration with
CIP (1.0 g/ml). For AZM the lowest growth-inhibitory con-
centration was 4.0 g/ml, and M. paratuberculosis was highly
resistant to NAL (inhibitory concentration  64.0 g/ml) (Ta-
ble 2).
Among the immunomodulatory drugs, the SS drug family (SS,
5-ASA, and SP) showed no significant anti-M. paratuberculosis
activity even at high concentrations (64.0 g/ml). Unexpectedly,
6-MP showed anti-M. paratuberculosis activity similar in potency
to that of CIP (lowest inhibitory concentration  1.0 g/ml) by
the MGIT 960 drug susceptibility test (Table 2).
Phase II. The susceptibility of M. paratuberculosis to 6-MP
was confirmed, and similar results were found for its precursor
drug, AZA (Table 3). Across the seven M. paratuberculosis
strains tested, growth inhibition for 6-MP was comparable to
that found for CIP in concentrations ranging from 1.0 to 4.0
g/ml. It required twofold-larger amounts of AZA to inhibit
growth, with concentrations ranging from 2.0 to 8.0 g/ml.
Mycobacterium avium (ATCC 35712) was resistant to both
thiopurine drugs, even at the 64.0 g/ml (Table 3).
In general, M. paratuberculosis isolates originating from
Crohn’s disease patients were more susceptible to thiopurine
drugs than were bovine-origin isolates among tested strains.
The patterns of drug susceptibility to CIP were the same re-
gardless of isolate origin. One human isolate, UCF-7, failed to
grow after 56 days of incubation in MGIT ParaTB medium
TABLE 2. Tested drugs in phase I experiment and their effect on
M. paratuberculosis ATCC 19698, as determined by MGIT
960a and agar plate counting methods
Drug Drug family/type
Lowest concn
(g/ml) producing
inhibition in
comparison with
1:100 dilution
control by:
Minimum drug
concn resulting
in no detectable
growth of M.
paratuberculosisb
MGIT 960
Agar
counting
method
AZM Macrolide 4.0 4.0 16.0
CIP Quinolone 1.0 1.0 32.0
NAL Quinolone 64.0 64.0 64.0
RIF First-line tuberculosis
drug
2.0 2.0 64.0
SP Sulfonamide 64.0 64.0 64.0
SS Sulfonamide 64.0 64.0 64.0
5-ASA Anti-inflammatory 64.0 64.0 64.0
6-MP Anti-inflammatory 1.0 1.0 32.0
a Each tube was inoculated with 106 CFU bacteria.
b Signal negative by the BACTEC MGIT 960 instrument up to 56 days post-
inoculation.
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containing 8.0 g/ml 6-MP or 16.0 g/ml AZA, while the
growth of the other strains was eventually detected even in the
presence of 32.0 g/ml 6-MP or AZA.
Phase III. Phase III verified the susceptibility of M. paratu-
berculosis to thiopurine drugs and showed that the effect was
relatively specific for this mycobacterial species. Both 6-MP
and AZA showed a stronger in vitro antimicrobial activity
against 11 M. paratuberculosis strains than 7 M. avium strains;
however growth inhibition patterns for thiopurine drugs
against M. avium strains varied widely. The mean 6-MP con-
centrations for M. paratuberculosis growth inhibition ranged
from 1.0 to 4.0 g/ml, while those for M. avium ranged 8.0 to
128.0 g/ml. Among M. avium strains, lower concentrations
of the test compounds were needed to inhibit growth for iso-
lates originating from water compared to clinical samples. The
6-MP initial inhibition range for human-origin M. paratuber-
culosis was 1.0 to 2.0 g/ml, while for bovine-origin strains it
ranged from 2.0 to 4.0 g/ml. Again, 6-MP was found to inhibit
M. paratuberculosis growth at one-half the concentration of
AZA regardless of M. paratuberculosis strain origin. This find-
ing was observed in other susceptible mycobacteria as well. No
growth in MGIT ParaTB medium with 8.0 to 16.0 g/ml of
6-MP was observed for three of the five Crohn’s disease patient
M. paratuberculosis isolates by 56 days, while growth of all M.
avium strains was detected within 15 days at these same drug
concentrations (Table 4).
The mycobacterial control M. phlei was as susceptible to
thiopurine drugs as M. paratuberculosis, but M. smegmatis
growth was completely resistant at 128 g/ml of both thiopu-
rine drugs. No antibacterial activity of thiopurine drugs against
E. coli or E. faecalis was found, even at the highest concentra-
tion tested (128.0 g/ml) (Table 4).
Comparison of drug actions against M. paratuberculosis. The
drugs studied were either bacteriostatic or bactericidal or had
no effect on M. paratuberculosis. Those with no effect, as evi-
denced by both plate count and MGIT 960 TTD data after
either 3 or 5 days of bacterial exposure to the drugs, included
the sulfonamide family (SS, SP, and 5-ASA; data not shown)
and NAL (Fig. 1A).
Antimicrobial drugs AZM, CIP, and RIF were bactericidal
for M. paratuberculosis. The minimum concentration for each
drug needed to kill the organism was defined as the drug
concentration producing fewer CFU than the non-drug-con-
taining 1:100 inoculum dilution control (Fig. 1A and B). Killing
concentrations for AZM and CIP by plate counting and MGIT
methods were in agreement. In the presence of RIF at lower
doses, viable M. paratuberculosis numbers initially declined but
then the organism resumed growth (Fig. 2C). Bovine- and
human-origin M. paratuberculosis strains were similarly af-
fected by the compounds; M. paratuberculosis was more sus-
TABLE 3. Lowest concentration to inhibita and concentration to killb seven M. paratuberculosis strains and one M. avium type strain by the
MGIT 960 drug susceptibility test
Drug
Concn (g/ml) required to inhibit (kill)
M. paratuberculosis strain: M. avium
ATCC 35712JTC303 UCF-4 UCF-5 UCF-7 B213 B236 B238
6-MP 1.0 (32.0) 2.0 (32.0) 1.0 (32.0) 1.0 (8.0) 4.0 (32.0) 4.0 (32.0) 4.0 (32.0) 64.0
AZA 2.0 (32.0) 4.0 (32.0) 2.0 (32.0) 1.0 (16.0) 8.0 (32.0) 8.0 (32.0) 16.0 (32.0) 64.0
AZM 1.0 (4.0) 1.0 (2.0) 0.5 (2.0) 0.5 (1.0) 1.0 (2.0) 0.5 (4.0) 0.5 (1.0) 1.0 (16.0)
CIP 2.0 (8.0) 1.0 (4.0) 2.0 (4.0) 1.0 (4.0) 4.0 (16.0) 4.0 (16.0) 4.0 (16.0) 16.0 (64.0)
a The lowest drug concentration producing a TTD greater than that for the 1:100 inoculum dilution control tube.
b Signal negative by the BACTEC MGIT 960 instrument for up to 56 days postinoculation.
TABLE 4. Lowest concentrations of two thiopurine drugs to
inhibita and killb strains of M. paratuberculosis,
M. avium, M. smegmatis, and M. phlei
Bacterial strain
Lowest concn of:
6-MP for: AZA for:
Inhibition Killing Inhibition Killing
M. paratuberculosis
ATCC 19698 1.0 16.0 2.0 16.0
UCF-3 1.0 8.0 2.0 32.0
UCF-4 2.0 32.0 4.0 32.0
UCF-5 1.0 32.0 2.0 32.0
UCF-7 1.0 8.0 2.0 16.0
UCF-8 1.0 16.0 2.0 32.0
B213 2.0 32.0 4.0 32.0
B236 4.0 32.0 4.0 32.0
B238 2.0 32.0 4.0 32.0
B244 4.0 32.0 8.0 32.0
M. avium
ATCC 35712 64.0 64.0 64.0 64.0
ATCC 25291 64.0 64.0 64.0 64.0
104 64.0 64.0 64.0 64.0
JTC4862 32.0 64.0 64.0 64.0
JTC981 64.0 64.0 64.0 64.0
EPA3 16.0 64.0 32.0 64.0
WSLH1544 8.0 64.0 32.0 64.0
Rapid growing
mycobacteria
M. phlei ATCC
11758
1.0 16.0 2.0 32.0
M. smegmatis
ATCC 14468
128.0 128.0 128.0 128.0
M. smegmatis
mc2155
128.0 128.0 128.0 128.0
Nonmycobacterial
controls
E. coli ATCC
25922
128.0 128.0 128.0 128.0
E. faecalis
ATCC 29212
128.0 128.0 128.0 128.0
a The lowest drug concentration producing a TTD greater than that for the
1:100 inoculum dilution control tube.
b Signal negative in the BACTEC MGIT 960 instrument for up to 56 days
postinoculation.
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ceptible to these antibiotics than was the control M. avium
strain tested (Table 3). The concentration of CIP required for
complete M. paratuberculosis growth inhibition after up to 56
days of incubation in MGIT ParaTB medium for human iso-
lates was twofold lower than that for bovine isolates, i.e., 4.0
g/ml and 16.0 g/ml, respectively.
Thiopurine drugs AZA and 6-MP inhibited M. paratubercu-
losis growth in a dose-dependent fashion. Plate count CFU
FIG. 1. Inhibition of M. paratuberculosis ATCC 19698 growth by exposure to NAL, CIP, and 6-MP at 1 to 64 g/ml for 3 or 5 days as determined by agar
plate counts, and the impact of the same drug concentrations on TTD in MGIT ParaTB medium, as monitored by the BACTEC MGIT 960 instrument.
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were lower than the number obtained by the MGIT 960 culture
counting method but generally higher than that for the 1:100
dilution control after both 3 and 5 days of M. paratuberculosis
exposure to the drugs (Fig. 1C). The effect of these drugs
appeared more profound by the MGIT 960 drug susceptibility
method, where there was continuous contact of the drug with
M. paratuberculosis in broth, i.e., the TTD was greater than that
for the 1:100 inoculum dilution control for all concentrations
of drug tested (1.0 g/ml). MGIT 960 analysis also showed a
direct relationship between AZA or 6-MP concentration and
suppression of M. paratuberculosis growth, i.e., longer TTD.
Mycobacterial species specificity for thiopurine drugs. Not
all mycobacterial species were affected by thiopurine drugs to
the same extent: M. paratuberculosis and M. phlei were suscep-
tible to growth inhibition effects, but M. avium and M. smeg-
matis were not (Fig. 3).
Phase IV. Exposure to 2 g/ml 6-MP resulted in lower M.
paratuberculosis CFU than the CFU in the 1:100 inoculum
dilution control at every drug exposure time beyond 6 days.
Simultaneous exposure of M. paratuberculosis to 6-MP and CIP
at the same concentrations resulted in significantly higher CFU
than use of CIP alone (Fig. 4).
DISCUSSION
Results for the antimicrobial susceptibility of M. paratuber-
culosis to standard drugs were consistent between plate count-
ing and MGIT 960 methods (Fig. 1). When growth-suppressive
effects were observed, they were drug concentration depen-
dent. Additionally, the results were consistent with those pre-
viously reported (31, 45).
Immunosuppressive drugs in the sulfonamide family, SS,
5-AZA, and SP, had no effect on M. paratuberculosis growth, even
at 64 g/ml (Table 2). NAL was tolerated by M. paratuberculosis
up to the maximum concentration tested, 64.0 g/ml, supporting
its use in primary M. paratuberculosis culture media for suppres-
sion of contaminating microflora (Table 1 and Fig. 1).
AZM was bactericidal for M. paratuberculosis at concentra-
tions of 4.0 to 16.0 g/ml (Fig. 2A). These findings are in
agreement with reports of improved clinical status of Crohn’s
disease patients treated with macrolides (14). CIP, by contrast,
killed 1 to 3 log10 of M. paratuberculosis ATCC 19698 cells over
the first 5 to 8 days, and then a seemingly drug-resistant pop-
ulation of cells resumed growth at rates comparable to the that
for the drug-free controls (Fig. 2B). (An alternative explana-
tion for these results is that by day 8 the CIP was no longer
FIG. 2. Effect of AZM (A), CIP (B), RIF (C), and 6-MP (D) on the viability of M. paratuberculosis ATCC 19698 over time (up to 56 days),
as determined by standard plate counts (CFU).
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active, and future studies should evaluate residual drug activ-
ity.) Human-origin strains were more susceptible to CIP, with
complete killing of 105 CFU M. paratuberculosis in 12 to 26
days (Fig. 3A). RIF produced an M. paratuberculosis growth
pattern similar to that produced by CIP, i.e., transitory decline
in CFU followed by regrowth (Fig. 2B and C).
AZA drugs killed M. paratuberculosis. The thiopurine drug
6-MP suppressed its growth more than did AZA at the same
FIG. 3. Effect of AZM, CIP, and 6-MP on the viability of M. paratuberculosis strain UCF-5 (A), M. avium ATCC 35712 (B), M. phlei ATCC
11758 (C), and M. smegmatis mc2155 (D) over time (up to 56 days), as determined by agar plate counts (CFU).
FIG. 4. Effect of CIP, 6-MP, and the combination of the two drugs both at 2 g/ml (A) and 4 g/ml (B) on the viability of M. paratuberculosis
strain UCF-7 after 12 days of drug exposure as determined by MGIT 960 counting methods (38).
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concentrations (g/ml). If MGIT drug susceptibility standards for
M. tuberculosis were used to interpret the data for 6-MP versus M.
paratuberculosis, growth was suppressed at 2.0 g/ml (poten-
tially the MIC) compared with the 1:100 drug-free growth control
(Fig. 2D). However, growth of M. paratuberculosis was not com-
pletely stopped, even at 16 g/ml 6-MP, but was simply slowed in
comparison to that of drug-free controls. Human-origin (Crohn’s
disease patient) isolates of M. paratuberculosis tended to be more
susceptible to 6-MP than were bovine-origin isolates (Table 4).
These findings are comparable to those reported by Greenstein et
al. using the BACTEC 460 system for M. paratuberculosis in in
vitro susceptibility studies (13, 45).
The growth-suppressive effects of 6-MP differed by myco-
bacterial species. These data suggest a possible mycobacterial-
species-specific mechanism by which 6-MP interferes with rep-
lication or metabolism.
The antimycobacterial effect of thiopurine drugs is a novel
and unexpected observation. The implications of the present
study for the possible etiologic role of M. paratuberculosis in
Crohn’s disease and approaches to Crohn’s disease therapy are
important. Some investigators describe the failure of M. para-
tuberculosis to multiply in the face of immunosuppressive ther-
apy with thiopurine drugs as evidence that Crohn’s disease
cannot be caused by M. paratuberculosis (35). Perhaps this
pathogen, found in resected bowel tissue and peripheral blood
leukocytes of some Crohn’s disease patients (6, 25, 36), is held
in check by thiopurine therapy since it has both immunosup-
pressive and anti-M. paratuberculosis activity.
These data also offer another perspective on data from clin-
ical trials with Crohn’s disease patients using antimycobacterial
drugs. Since patients in the “control” group are maintained on
standard therapy (which commonly employs thiopurine drugs),
both the treatment group (antimycobacterial drugs) and con-
trol group (no antimycobacterial drugs but continued thiopu-
rine drugs) are exposed to compounds with anti-M. paratuber-
culosis activity. If M. paratuberculosis is integral to Crohn’s
disease, then the opportunity to observe clear-cut therapeutic
differences between the treatment and control groups in these
trials is limited.
Antimycobacterial and thiopurine drugs used in concert may
produce an interactive effect. The apparently bacteriostatic
effects of 6-MP on M. paratuberculosis rendered the organism
less susceptible to the bactericidal effects of CIP. This further
complicates interpretation of many of the prior clinical trials
with Crohn’s disease patients that employed antimicrobials in
addition to immunosuppressive drugs. Given the potential side
effects of these medications, pursuit of therapeutic trials with
patients in the absence of sound in vitro data is both premature
and inappropriate.
A major challenge for antimicrobial susceptibility studies of
M. paratuberculosis is its long generation time, i.e., roughly 2
days (24), and uncertainty about the stability of the test drugs
in MGIT ParaTB medium at 37°C over the course of incuba-
tion. Without accepted standards for M. paratuberculosis anti-
microbial susceptibility testing, it was vital that multiple meth-
ods and controls be employed and that results be descriptive
and interpreted in relative rather than absolute terms such as
“susceptible” or “resistant.” Multiple mycobacterial species as
well as nonmycobacterial species were needed as antibiotic
susceptibility quality control standards. We also assessed
whether drugs had an inhibitory or lethal effect on target or-
ganisms by subculture to drug-free media. More-extensive in
vitro drug susceptibility trials with M. paratuberculosis are re-
quired to establish which drugs are most efficacious and which
drugs, when used in combination, have a modulated effect on
M. paratuberculosis. While the results of this research are pro-
vocative, expanded studies should include an assessment of the
stability and activity of antimicrobial drugs in MGIT ParaTB
medium at 37°C over the extended incubation period required
for M. paratuberculosis drug susceptibility testing.
This work is hypothesis generating, not definitive. Method-
ological issues, in particular, that the mycobacteria were tested
in an extracellular location, and the limited number of strains
of each mycobacterial species tested are among just some of
the caveats regarding extension of these findings to the clinical
situation. However, this work highlights the complexity of
studying M. paratuberculosis interactions with antibiotics and
the possibility that anti-inflammatory drugs may exert antibac-
terial effects directly on this organism and/or have negative
interactions with conventional antimicrobial drugs. These ca-
veats argue against simple adoption of drug susceptibility test-
ing methods used for M. tuberculosis or M. avium and for
more-comprehensive characterization of the bactericidal or
growth-inhibitory effects of antimicrobial and anti-inflamma-
tory drugs alone and in combination on M. paratuberculosis.
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